Assertio Holdings, Inc. (NASDAQ: ASRT) has agreed to be acquired by Garda Therapeutics, Inc. for $18 per share in cash, a total consideration of $125.1 million. The deal also contains a contingent value right that will trigger additional payment if a Sprix milestone is reached, giving Assertio shareholders upside beyond the cash offer.
Under the agreement, Assertio will sell all non‑Rolvedon assets—Indocin, Sympazan, Sprix, Cambia, Zipsor, and Otrexup—to Cosette Pharmaceuticals for an upfront payment of $35 million plus earn‑outs tied to product milestones. The divestiture is intended to streamline Assertio’s focus on its oncology platform centered around Rolvedon and to monetize legacy products.
The transaction reflects a strategic pivot away from the company’s previous model of acquiring on‑market specialty products, a shift that CEO Mark L. Reisenauer described as “no longer capital efficient or a sustainable strategy to fuel growth.” CFO Ajay Patel noted that “Total product sales in the fourth quarter were $12.8 million compared to $29.6 million in the prior year, primarily driven by the timing of channel inventory associated with the previously disclosed Rolvedon sell‑in.” The deal therefore positions Garda to build a pure‑play oncology business while Assertio exits its legacy portfolio.
Financially, Assertio’s Q4 2025 results showed a 57% decline in product sales to $12.8 million versus $29.6 million a year earlier, and the company posted a net loss from operations of $21.5 million. Adjusted EBITDA rose to $22.7 million from $18.3 million in 2024, driven by a higher gross margin of 70% versus 68% in 2024 and a 75% margin in Q4 2025 compared with 61% a year earlier. Despite these margin gains, revenue growth has been negative—down 24.4% over the past three years—and the Altman Z‑Score of –2.77 signals financial distress.
Following the announcement, analysts at Lake Street and H.C. Wainwright downgraded Assertio to Hold and Neutral, respectively, and lowered their price targets to the offer price of $18 from $45 and $35. Retail investors expressed disappointment, noting that the offer price was close to the stock’s recent trading level. The market reaction underscores the premium paid and the perceived value of the oncology focus.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. Upon completion, Assertio’s common stock will be delisted from Nasdaq, and shareholders will receive the agreed cash payment and any applicable contingent value right proceeds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.